Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label, Single-arm Study to Demonstrate the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Chinese Subjects Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate-, Posterior-, or Pan-uveitis
Conditions
Interventions
Adalimumab
Locations
7
China
Peking University First Hospital /ID# 243055
Beijing, Beijing Municipality, China
Shanghai General hospital /ID# 247252
Shanghai, Shanghai Municipality, China
The second affiliated hospital of Zhejiang University school of medicine /ID# 247251
Hangzhou, Zhejiang, China
Eye hospital,WMU Zhejiang Eye Hospital /ID# 247253
Wenzhou, Zhejiang, China
Beijing Tongren Hospital, CMU /ID# 243054
Beijing, China
Tianjin Medical University Eye Hospital /ID# 243056
Tianjin, China
Start Date
July 7, 2022
Primary Completion Date
June 10, 2024
Completion Date
June 10, 2024
Last Updated
June 10, 2025
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions